A man with recurrent hypovolemic shock on anti –programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy

Immune checkpoint inhibitors (ICIs) have been recently incorporated in the standard clinical practice for patients with cancer. ICI treatment occasionally causes side-effects related to their mode of action, called immune-related adverse events (irAEs). Recently, major oncology societies have provided grading systems and treatment guidelines for irAEs in patients treated with ICIs [1]. However, immunotherapy has been introduced in clinical practice for less than a decade. Therefore, insufficient clinical data have been accumulated for their acute complications, and the long-term side-effects have not been sufficiently evaluated.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research